Selol nanocapsules with a poly(methyl vinyl ether-co-maleic anhydride) shell conjugated to doxorubicin for combinatorial chemotherapy against murine breast adenocarcinoma in vivo

Abstract

Nanocapsules containing selol and doxorubicin (NCS-DOX) with an oily core of selol and a shell of poly(methyl vinyl ether-co-maleic anhydride) covalently conjugated to doxorubicin were developed in a previous work. In this study, these nanocapsules showed a similar antitumour effect in comparison to the free doxorubicin (DOX) treatment, but showed no evident DOX-related cardiotoxicity, as evidenced by serum creatine kinase-MB (CK-MB) activity. The histopathological analysis showed that the free DOX treatment induced more intense morphological damage to myocardial tissues in comparison to NCS-DOX treatment. Animals treated with free DOX presented important muscle fibre degradation and animals treated with NCS-DOX, heart tissue did not present signals of muscle fibre degeneration. These results indicate that the cardiotoxicity related to DOX is reduced when this drug is carried by the NCS-DOX. Noteworthy, biodistribution analyses showed that NCS-DOX accumulated more intensely in tumours than the free DOX. Thus, this study reinforces the importance of the development of nanocapsules as drug carriers for the treatment of cancer.

Nanomedicine for Cutaneous Tumors – Lessons Since the Successful Treatment of the Kaposi Sarcoma

“…All these positive results observed in the treatment of Kaposi's sarcoma reinforced the expectation that nanomedicines could act as 'magic bullets' to fight cancer, referring to Paul Ehrlich's well-known phrase [7]. In addition to these first clinical outcomes, thousands of preclinical studies demonstrated that the nanoparticles were passively accumulated by tumors, due to the classical enhanced permeability and retention (EPR) effect, further reinforcing this expectation [1,4,8,9]. Nowadays, Doxil is commercially used and presents superior performance over conventional therapies for the following tumor types: HIV-related Kaposi's sarcoma; metastatic breast cancer; recurrent ovarian cancer; and multiple myeloma [5].…”

“…Thus, in a prospective view toward future nanomedical developments, researchers should consider the biological behavior of each tumor type individually, and they should invest in alternative additive strategies in addition to the EPR effect. It is important to highlight that our research group truly believes that prospective approaches, such as the use of external active triggers [9], co-delivery of chemotherapeutical drugs [8], active delivery systems [11] and controlled-release systems, can offer possible effective solutions to improve cancer therapy using nanotechnology and nanocarriers.…”

Review of the Mechanism of Nanocarriers and Technological Developments in the Field of Nanoparticles for Applications in Cancer Theragnostics

“…So, nanocapsules can be considered perfect for the preparation of a drug that is lipid-soluble . Lipid NPs are generally employed in overcoming the drug resistance which is mediated by P-gp and nanosponge is one example for the same. , Research has shown that nanoparticles made up of polyalkyl­cyanoacrylate have the capacity to reverse the P-gp activity by making use of a process called endocytosis process…”

“…243 Lipid NPs are generally employed in overcoming the drug resistance which is mediated by P-gp and nanosponge is one example for the same. 244,245 Research has shown that nanoparticles made up of polyalkylcyanoacrylate have the capacity to reverse the P-gp activity by making use of a process called endocytosis process. 246 It was also observed that in terms of cellular uptake and cytotoxicity, the chemotherapy which is mediated by polyisohexylcyanoacrylate (PIHCA) nanoparticles performed better when compared to free drugs.…”

Cancer Nanomedicine: A New Era of Successful Targeted Therapy

“…Pharmaceutically, the liposome improves the pharmacokinetic and pharmacodynamic properties of the drug used; hence, the survival of cancer patients increases compared with parenteral drug treatment. 5 Journal of Nanomaterials nanocapsules) are commonly used to overcome P-gpmediated drug resistance [65]; an example of that is the use of nanosponge [66]. In vivo, polyalkylcyanoacrylate NPs can reverse P-gp activity by an endocytosis process [67].…”